Pharma & Biotech

Absci finds itself navigating turbulent financial waters as the biotechnology firm grapples with plunging revenue alongside aggressive investment in its...

Investors in Akero Therapeutics are bracing for a pivotal moment as the biopharmaceutical company approaches a decisive regulatory deadline. With...

While numerous biotechnology firms are scaling back expectations, Supernus Pharmaceuticals is projecting a surprisingly confident stance by reaffirming its annual...

Biotechnology firm Equillium is executing a profound strategic overhaul, pivoting its entire operational focus to a single, promising drug candidate....

For Replimune and its investors, 2026 is shaping up to be a defining period. After a significant regulatory setback in...

While Redcare Pharmacy shares continue their prolonged decline, having shed more than 60% from their December peak, a significant development...

The battle for dominance in the lucrative weight-loss medication sector has entered a new phase of competition. Novo Nordisk, the...

The fate of German biotech firm CureVac hangs in the balance as shareholders prepare for a landmark decision that could...

Johnson & Johnson's equity is demonstrating remarkable momentum, advancing for five consecutive trading sessions with a notable surge in volume...

The telehealth sector faces increasing regulatory scrutiny, and Hims & Hers Health, Inc. is making strategic moves to navigate these...